Takeda Pharmaceutical Company Limited
TAK
Jodie situation report
Takeda Pharmaceutical Company Limited's move is being confirmed by its market group.
No new filing conclusion is available. 8 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 25 directly disclosed connections are confirming.
- At least 10 of 15 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ABBV begins moving with the group.
Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.
Who this business touches
The relationships behind TAK
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
EXEL7.7% of EXELcustomerMay 5, 2026 ▾
“During the three months ended March 31, 2026, we recognized $7.7 million in revenues in connection with an $8.0 million commercial milestone payment from Takeda, which was earned upon their achievement of $300.0 million of cumulative net sales of cabozantinib…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 24 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TAK is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.